AXSOME THERAPEUTICS, INC. Advertising Expense
AXSOME THERAPEUTICS, INC. (AXSM) reported Advertising Expense of $55.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. advertising expense for the quarter ending 2026-06-30 was $55.10M, a 53.06% increase year-over-year.
- AXSOME THERAPEUTICS, INC. advertising expense for the quarter ending 2026-03-31 was $59.40M, a 114.44% increase year-over-year.
- AXSOME THERAPEUTICS, INC. advertising expense for the quarter ending 2025-12-31 was $62.00M, a 136.64% increase year-over-year.
- AXSOME THERAPEUTICS, INC. advertising expense for the quarter ending 2025-09-30 was $41.40M, a 100.00% increase year-over-year.
- AXSOME THERAPEUTICS, INC. advertising expense for fiscal 2025 was $167.10M, a 65.12% increase from fiscal 2024.
- AXSOME THERAPEUTICS, INC. advertising expense for fiscal 2024 was $101.20M, a 0.90% increase from fiscal 2023.
- AXSOME THERAPEUTICS, INC. advertising expense for fiscal 2023 was $100.30M, a 184.14% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. advertising expense for fiscal 2022 was $35.30M.
| Period end | Advertising Expense 3 month | Advertising Expense 6 month | Advertising Expense 9 month | Advertising Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $55.10M 10-Q · filed 2026-08-10 | $114.50M 10-Q · filed 2026-08-10 | $176.50M derived: sum of 3 quarters · filed 2026-08-10 | $217.90M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $59.40M 10-Q · filed 2026-05-04 | $121.40M derived: sum of 2 quarters · filed 2026-05-04 | $162.80M derived: sum of 3 quarters · filed 2026-05-04 | $198.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $62.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $103.40M derived: sum of 2 quarters · filed 2026-02-23 | $139.40M derived: sum of 3 quarters · filed 2026-08-10 | $167.10M 10-K · filed 2026-02-23 |
| 2025-09-30 | $41.40M 10-Q · filed 2025-11-03 | $77.40M derived: sum of 2 quarters · filed 2026-08-10 | $105.10M 10-Q · filed 2025-11-03 | $131.30M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $36.00M 10-Q · filed 2026-08-10 | $63.70M 10-Q · filed 2026-08-10 | $89.90M derived: sum of 3 quarters · filed 2026-08-10 | $110.60M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $27.70M 10-Q · filed 2026-05-04 | $53.90M derived: sum of 2 quarters · filed 2026-05-04 | $74.60M derived: sum of 3 quarters · filed 2026-05-04 | $104.90M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $26.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $46.90M derived: sum of 2 quarters · filed 2026-02-23 | $77.20M derived: sum of 3 quarters · filed 2026-02-23 | $101.20M 10-K · filed 2026-02-23 |
| 2024-09-30 | $20.70M 10-Q · filed 2025-11-03 | $51.00M derived: sum of 2 quarters · filed 2025-11-03 | $75.00M 10-Q · filed 2025-11-03 | $99.10M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $30.30M 10-Q · filed 2025-08-04 | $54.30M 10-Q · filed 2025-08-04 | $78.40M derived: sum of 3 quarters · filed 2026-02-23 | $106.50M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $24.00M 10-Q · filed 2025-05-05 | $48.10M derived: sum of 2 quarters · filed 2026-02-23 | $76.20M derived: sum of 3 quarters · filed 2026-02-23 | $102.90M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $24.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $52.20M derived: sum of 2 quarters · filed 2026-02-23 | $78.90M derived: sum of 3 quarters · filed 2026-02-23 | $100.30M 10-K · filed 2026-02-23 |
| 2023-09-30 | $28.10M 10-Q · filed 2024-11-12 | $54.80M derived: sum of 2 quarters · filed 2024-11-12 | $76.20M 10-Q · filed 2024-11-12 | $79.20M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $26.70M 10-Q · filed 2024-08-05 | $48.10M 10-Q · filed 2024-08-05 | $51.10M derived: sum of 3 quarters · filed 2025-02-18 | $64.90M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $21.40M 10-Q · filed 2024-05-06 | $24.40M derived: sum of 2 quarters · filed 2025-02-18 | $38.20M derived: sum of 3 quarters · filed 2025-02-18 | $47.30M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $16.80M derived: sum of 2 quarters · filed 2025-02-18 | $25.90M derived: sum of 3 quarters · filed 2025-02-18 | $35.30M 10-K · filed 2025-02-18 |
| 2022-09-30 | $13.80M 10-Q · filed 2023-11-06 | $22.90M derived: sum of 2 quarters · filed 2023-11-06 | $32.30M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $9.10M 10-Q · filed 2023-08-07 | $18.60M 10-Q · filed 2023-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |